Bacterial conjunctivitis: Children and Adolescents: Ophthalmic: Instill 1 drop into affected eye(s) 3 times daily (4 to 12 hours apart) for 7 days
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.
(For additional information see "Besifloxacin: Drug information")
Bacterial conjunctivitis: Ophthalmic: Instill 1 drop into affected eye(s) 3 times daily (4 to 12 hours apart) for 7 days.
There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.
1% to 2%:
Central nervous system: Headache
Ophthalmic: Conjunctival erythema (2%), blurred vision, eye irritation, eye pain, eye pruritus
There are no contraindications listed in the manufacturer's labeling.
Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to besifloxacin, any component of the formulation, or other quinolones.
Concerns related to adverse effects:
• Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with systemic quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.
• Superinfection: Prolonged use may result in fungal or bacterial superinfection. Discontinue use and initiate alternative therapy if superinfection occurs.
Special populations:
• Contact lens wearers: Contact lenses should not be worn during treatment of ophthalmic infections.
Dosage form specific issues:
• Ophthalmic solution: For topical ophthalmic use only. Do not inject ophthalmic solution subconjunctivally or introduce directly into the anterior chamber of the eye.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Suspension, Ophthalmic:
Besivance: 0.6% (5 mL) [contains benzalkonium chloride, edetate (edta) disodium dihydrate]
No
Suspension (Besivance Ophthalmic)
0.6% (per mL): $54.39
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Suspension, Ophthalmic:
Besivance: 0.6% (2 mL, 5 mL) [contains benzalkonium chloride, edetate (edta) disodium dihydrate]
Ophthalmic: For topical ophthalmic use only. Wash hands before and after instillation. Invert bottle while closed and shake bottle once prior to each administration. Avoid contaminating the applicator tip with affected eye(s), fingers, or other sources.
Ophthalmic: For topical ophthalmic use only. Wash hands before and after instillation. Invert bottle while closed and shake once prior to each administration. Avoid contaminating the applicator tip with affected eye(s), fingers, or other sources.
Store between 15°C to 25°C (59°F to 77°F). Protect from light.
Treatment of bacterial conjunctivitis (FDA approved in ages ≥1 year and adults)
None known.
There are no known significant interactions.
Systemic concentrations of besifloxacin following ophthalmic administration are low. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion for 3 to 5 minutes after application to decrease potential exposure to the fetus (Samples 1988).
Signs and symptoms of infection or hypersensitivity reaction
Inhibits both DNA gyrase and topoisomerase IV. DNA gyrase is an essential bacterial enzyme required for DNA replication, transcription, and repair. Topoisomerase IV is an essential bacterial enzyme required for decatenation during cell division. Inhibition effect is bactericidal.
Half-life elimination: ~7 hours
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟